Investigation of the effect of Myricetin on Cisplatin-induced liver hepatotoxicity
Rev. Assoc. Med. Bras. (1992, Impr.)
; 70(7): e20240136, 2024. tab, graf
Article
en En
|
LILACS-Express
| LILACS
| ID: biblio-1565048
Biblioteca responsable:
BR1.1
Ubicación: 1806-9282-ramb-70-07-e20240136.xml
ABSTRACT
SUMMARY OBJECTIVE:
Cisplatin, a widely used anticancer agent, induces hepatotoxicity alongside organ damage. Understanding Cisplatin's toxicity mechanism and developing preventive measures are crucial. Our study explores Myricetin, a flavonoid, for its protective effects against Cisplatin-induced hepatotoxicity.METHODS:
In our study, a total of 32 Wistar albino male rats were utilized, which were categorized into four distinct groups Control, Myricetin, Cisplatin, and Myricetin+Cisplatin. For the histological assessment of hepatic tissues, hematoxylin-eosin and periodic acid Schiff staining were employed, alongside immunohistochemical measurements of TNF-α, interleukin-17, and interleukin-6 immunoreactivity. Additionally, aspartate transaminase and alanine transaminase values were examined by biochemical analysis.RESULTS:
In the histological evaluation of the tissues, a normal healthy cell structure and a strong periodic acid Schiff (+) reaction were observed in the hepatocyte cells in the tissues of the Control and Myricetin groups, while intense eosinophilia, minimal vacuolization, congestion, and sinusoidal expansions were observed in the hematoxylin-eosin stainings, and a decrease in the positive reaction in the periodic acid Schiff staining was observed in the Cisplatin group. Consistent with these histological findings, an increase in TNF-α, interleukin-17, and interleukin-6 expressions (p<0.0001) and a concomitant increase in aspartate transaminase and alanine transaminase values were observed in the Cisplatin group. In the group protected by Myricetin, a significant improvement was observed in all these histological and biochemical values.CONCLUSION:
Cisplatin induces notable histopathological alterations in the liver. In this context, Myricetin exhibits the potential to alleviate Cisplatin-induced damage by modulating histological parameters and biochemical processes.
Texto completo:
1
Índice:
LILACS
Idioma:
En
Revista:
Rev. Assoc. Med. Bras. (1992, Impr.)
Asunto de la revista:
EducaÆo em Sa£de
/
GestÆo do Conhecimento para a Pesquisa em Sa£de
/
MEDICINA
Año:
2024
Tipo del documento:
Article